Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis A vaccine + diphtheria-tetanus-pertussis vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine that provides protection against hepatitis A virus infection and three bacterial diseases: diphtheria, tetanus, and pertussis (whooping cough). The diphtheria and tetanus components consist of inactivated toxoids, while the pertussis component may contain either killed whole cells or specific pertussis antigens in the acellular version. This combination reduces the number of injections needed while maintaining protection against multiple diseases.
Beyond the preview
Go deeper on hepatitis A vaccine + diphtheria-tetanus-pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis A vaccine + diphtheria-tetanus-pertussis vaccine.